Skip to main content


March 04, 2021
NEWS PROVIDED BY GO2 Foundation for Lung Cancer  SAN CARLOS, Calif. and WASHINGTON, March 4, 2021 /PRNewswire/ -- GO2 Foundation for Lung Cancer (GO2 Foundation) announced its leadership in the launch of an important…
March 01, 2021
Blue Earth Diagnostics utilizing ERT imaging solution to evaluate a novel imaging agent for potential use to inform brain metastases disease management
February 17, 2021
LONDON, Feb. 17, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, today announces a research collaboration with Essen University Hospital to examine…
February 05, 2021
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark warnings on liver cancer survival rates.
February 02, 2021
Join us in Miami for the practical IO meeting of the year!
February 01, 2021
GPX Embolic Device Showcased at Leipzig Interventional Course (LINC) for Interventional Oncology Embolizations
December 31, 2020
Non-Invasive Drug-Device Treatment Aims to Target Brain Cancers Selectively, Turning them from Lethal Diseases into Manageable Conditions: Led by Experts with Decades of Experience Developing and Commercializing Drug-Device Systems in Photodynamic…
November 23, 2020
Novel Interventional Oncology Embolization Device Successfully Used in Trans-Radial Access Procedures for Tumor Devascularization
November 23, 2020
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that positive clinical data based on a…
November 23, 2020
ORIENT-32 is the first randomized Phase 3 study reporting the efficacy and safety of an anti-PD-1 antibody-based combination therapy versus sorafenib as the first-line treatment in patients with advanced unresectable hepatocellular carcinoma (HCC).
Back to Top